What to Expect With GBT’s Upcoming Phase 3 Part A Data
Insights - Global Blood Therapeutics (GBT) Phase 3 Part A data should be out sometime in the next month (read about timeline here). GBT is expected to report … Continue Reading
Premium: Read NowInsights
Selecta’s Data Causes Selloff, But It Was Actually Immaterial
Insights - Selecta provided an update this morning for their dose escalating trial for the co-administration of: 1. 0.125mg/kg of SVP-rapamycin + 0.4mg/kg of pegsiticase 2. 0.15 … Continue Reading
Read Now
Markets Overlooking SWKH as Company Continues Executing
Insights - SWK Holdings (SWKH) announced Q4 and full year 2017 earnings earlier this week and the company is continuing to execute on their business. We initially discussed SWK … Continue Reading
Premium: Read Now
Selecta’s Data in Q3: De-Risking Event, Not a Delay
Insights - Selecta held a conference call to discuss their Q4 2017 results and provided a corporate update. Overall, we believe the call was positive and shed light … Continue Reading
Premium: Read NowA Second KOL’s Thoughts on Selecta
Insights - On March 20th, 2018 SlingShot Insights hosted a KOL call with Dr. Dr Gail Kerr – MD, discussing Selecta (SELB) candidate SEL-212 and Krystexxa, the … Continue Reading
Premium: Read Now
Fennec’s Fast Track & Breakthrough Designations Pointing to Smooth FDA Review
Insights - This morning, Fennec (FENC) announced that the FDA had granted the company’s candidate, Pedmark, Breakthrough Therapy Designation for the prevention of cisplatin-related ototoxicity in pediatric patients with … Continue Reading
Read NowHere is What a KOL Had to Say About Selecta
Insights - On Thursday, March 8th, 2018 SlingShot Insights hosted a KOL call with Dr.Vibeke Strand, discussing Selecta (SELB) and the current treatments for gout. Below are … Continue Reading
Premium: Read Now